Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: heart disease

Recent Study Improves Understanding of Preclinical Rheumatoid Arthritis

  |  

A study recently published in Arthritis Care & Research (AC&R) reveals a novel approach for the study of preclinical rheumatoid arthritis (RA). The investigators conducting the study sought to determine if these RA-related biomarkers could also be found in healthy subjects in order to investigate relationships between genetic and environmental factors and the presence of these biomarkers. Their goal is to study how these biomarkers evolve.

Letters to the Editor: In Memoriam

The Rheumatologist  |  

One more prescribing rule [See “Rheuminations,” September 2009, p. 6], honored mainly in the breach, in our overspending climate: don’t prescribe an expensive brand when generics are as good or better, especially Nexium (which I have never prescribed) versus omeprazole, Lipitor versus simvastatin (which now costs the VA three cents a pill), and—for rheumatologists who are writing 80% Uloric—allopurinol except for the 10% who might need Uloric.

Within Our Reach–Funded Research May Hold Key to Unlocking the CNS and Suppressing RA

  |  

Studies recently published in Arthritis & Rheumatism show that a key chemical produced by the central nervous system (CNS) decreases inflammation and suppresses production of proteins known to play a role in rheumatoid arthritis (RA). This opens the way for developing a novel class of drugs that mimic this effect of the CNS on RA.